Publication Policy. The results of the study are the property of the Sponsor. All manuscripts, abstracts or other modes of presentation arising from the results of the study must be reviewed and approved in writing by the Sponsor, in advance of submission. Co-authorship with any Sponsor personnel will be discussed and mutually agreed upon before submission of a manuscript to a publisher. 11 References
Publication Policy. As described in the Enroll-HD Publication Policy (as amended from time to time), it is CHDI's position that all matters related to authorship of scientific publications resulting wholly or in substantial part from CHDI resources (financial support, data or biomaterials) should be determined in accordance with the criteria defined by the International Committee of Medical Journal Editors (xxxx://xxx.xxxxx.xxx/recommendations/browse/roles-and- responsibilities/defining-the-role-of-authors-and-contributors.html). The Recipient acknowledges that, when publishing any Research Results, the Recipient is expected to comply with the Enroll-HD Publication Policy (as amended from time to time).
Publication Policy. As described in CHDI's Publication Policy (as amended from time to time), it is XXXX's position that all matters related to authorship of scientific publications resulting wholly or in substantial part from CHDI resources (financial support, data or biomaterials) should be determined in accordance with the criteria defined by the International Committee of Medical Journal Editors (xxxx://xxx.xxxxx.xxx/recommendations/browse/roles-and- responsibilities/defining-the-role-of-authors-and-contributors.html). The Recipient acknowledges that, when publishing any Research Results, the Recipient is expected to comply with (i) CHDI's Publication Policy and
Publication Policy. Publications arising from the iLocater program are governed by a co-author policy which encompasses people who are directly involved in the work included in the publication (the Authors List) and those people who have indirectly enabled it to be completed (Builder’s List and Regular List). Generally, all authors should be existing members of, or be invited to join, the iLocater collaboration. For technical publications, for example SPIE Proceedings or similar papers covering the detailed design of the instrument, these will include (in order) the Authors List and Builder’s List. For science publications in journals or conference proceedings, for example ApJ, MNRAS etc., these will include (in order) the authors, the Builder’s List and the Regular List. It may also be appropriate to invite any observers as co-authors or to include an acknowledgment of their contributions. Any author (Builder’s List or Regular List) who made a significant contribution to the paper can be listed in earlier sections of the Author’s List, with the first author deciding the order. The Builder’s and Regular List will be agreed by the Co-PIs and reviewed on an annual basis (in January) or as required. All team members (Authors, Builder’s and Regular list) should be explicitly notified by email regarding any publications relating to the collaboration to allow them to opt-in or opt-out as a co- author. Sufficient and realistic time should be given to those invited (10+ business days).
Publication Policy. The Patient Registry Committee must be consulted on any publications resulting from use of the requested data. This will help assure that the interpretations and conclusions of the authors are accurate and consistent with the scientific objectives initially stated in the proposal. It is helpful to specify all proposed collaborators/co-authors at the time of your data request. When abstracts, exhibits, invited papers or manuscripts are prepared using the FSR S.A.R.C. Registry data, the work must include the following acknowledgement: “The authors would like to thank the Foundation for Sarcoidosis Research for the use of FSR S.A.R.C. Patient Registry data to conduct this study.” FSR requires that no individually identifiable information from the FSR S.A.R.C. Patient Registry shall be included in publications, and other written products based on the data request. Data must be presented in the aggregate. All tables generated from registry data should include a patient count of five or more in each cell. FSR recognizes that journals are increasingly shifting to transparency of data presented in their publications and we acknowledge that journals prefer to have data shared and stored in a repository available to other researchers. Though this is a preference for most journals, we ask that you please include the below statement when submitting a manuscript as FSR is committed to data security and the confidentiality of patients who voluntarily provide data to the FSR S.A.R.C. Registry: “Data is available upon request through the FSR
Publication Policy. The results of the study are the property of the Sponsor. All manuscripts, abstracts or other modes of presentation arising from the results of the study must be reviewed and approved in writing by the Sponsor, in advance of submission. Co-authorship with any Sponsor personnel will be discussed and mutually agreed upon before submission of a manuscript to a publisher. Annotated Protocol incorporating Amendment 1, Amendment 2, Amendment 3, and Amendment 4 01 December 2008 Protocol BL-1040.01, Version 5.00 Safety and Feasibility study of BL-1040 Final CONFIDENTIAL 11 References
Publication Policy. All information concerning SAGE-217 is considered confidential and shall remain the sole property of Sage Therapeutics. The investigator agrees to use this information only in conducting the study and shall not use it for any other purposes without written approval from Sage Therapeutics. No publication or disclosure of study results will be permitted except as specified in a separate, written, agreement between Sage Therapeutics and the investigator.
Publication Policy. For the purposes of this Article VIII, “publication” shall be deemed to mean any written, oral, or other public divulgence including, but not limited to technical publications, press releases, and presentations, of the results of any Institute Research to the extent that any such divulgence could bar the availability of patent protection in foreign jurisdictions or trigger the one-year grace period in the U.S. within which a U.S. patent application must be filed. Publication of research results in scientific journals is encouraged. In order to prevent untimely publication of patentable research, any person who desires to publish the results of Institute Research shall provide notification of such intent to publish to the Executive Director and Chief Technology Officer. The Executive Director can require a maximum three-month delay, but shall require no less than a thirty-day delay, in publication from the date of notification to determine whether the paper contains patentable material, a Member’s Confidential Information or a trade secret. Upon consultation with the relevant Members whose Confidential Information may be at issue, if it is determined that patentable material is contained in the proposed publication, the Executive Director will direct that such material will be either deleted and publication will be allowed to proceed, or that publication will be delayed for another three months until all necessary intellectual property rights have been secured through filing of patent applications. In the unlikely event that the publication contains Confidential Information or trade secret information of a Member, that information will be removed from the publication. Any requirement to delete information or delay publication must be communicated to the proposed publisher within thirty (30) days of receipt of notification of intent to publish. Under no circumstances shall a student’s thesis, based in whole or in part on Institute Research, be delayed in degree confirmation; provided, however, that student theses shall be subject to a six-month delay provision following their approval before they are made publicly available; and provided, further, that Member Universities may be released from this six-month delay period if a U.S. patent application is placed on file which covers the subject matter of the thesis. Students of universities other than NC State shall be afforded the publication delays for theses contained in the policies of those universities.
Publication Policy. The CDF Research Committee may be consulted on any publications resulting from use of the requested data. This will help assure that the interpretations and conclusions of the authors are accurate and consistent with the scientific objectives initially stated in the proposal. It is helpful to specify all proposed collaborators/co-authors at the time of your data request. When abstracts, exhibits, invited papers or manuscripts are prepared using the iCureCeliac® data, the work must include the following acknowledgement: The authors would like to thank the Celiac Disease Foundation for the use of iCureCeliac® data to conduct this study. CDF requires that no individually identifiable information from iCureCeliac® shall be included in publications, and other written products based on the data request. Data must be presented in the aggregate. All tables generated from registry data should include a patient count of five or more in each cell. CDF recognizes that journals are increasingly shifting to transparency of data presented in their publications and we acknowledge that journals prefer to have data shared and stored in a repository available to other researchers. Though this is a preference for most journals, you must include the below statement when submitting a manuscript as CDF is committed to data security and the confidentiality of patients who voluntarily provide data to iCureCeliac®. CDF maintains copies of all data sets sent to researchers, and if you are audited, we can provide you with the data again. Suggested data availability language: Data is available upon request through the CDF Research Committee. You can contact the committee at xxxxxxxxxxx@xxxxxx.xxx. Restrictions on access to data are to ensure patient privacy for all persons in iCureCeliac®. Prior to the submission of abstracts, poster presentations, or manuscripts a copy must be sent to xxxxxxxxxxx@xxxxxx.xxx for review by CDF Research Committee members. We request 30 days for manuscripts and seven days for abstracts. In addition, once the abstract or manuscript are accepted by a scientific organization, one copy of said paper, or a suitable description of the exhibit, shall be forwarded to CDF on notice of such acceptance, together with the name of the publication or the organization accepting it, and the time and place of the scientific meeting.
Publication Policy. The results of this study may be published or presented at scientific meetings. If this is foreseen, the Investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments. The Sponsor will comply with the requirements for publication of study results. In accordance with standard editorial and ethical practice, the Sponsor will generally support publication of multicenter studies only in their entirety and not as individual site data. In this case, a coordinating Investigator will be designated by mutual agreement. Authorship will be determined by mutual agreement and in line with International Committee of Medical Journal Editors authorship requirements.
